These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1524 related items for PubMed ID: 30713085

  • 1. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

  • 3. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D.
    Cardiovasc Diabetol; 2021 Oct 18; 20(1):210. PubMed ID: 34663316
    [Abstract] [Full Text] [Related]

  • 4. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K.
    Cardiovasc Diabetol; 2022 Mar 16; 21(1):42. PubMed ID: 35296336
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 8. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 9. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 06; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 10. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K.
    JAMA; 2018 Apr 17; 319(15):1580-1591. PubMed ID: 29677303
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 17; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC, Botros FT, Atisso CM, Sager PT.
    Cardiovasc Diabetol; 2016 Feb 24; 15():38. PubMed ID: 26912057
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS, Lee JK, Hung CS, Chen WJ.
    Diabetologia; 2021 Dec 24; 64(12):2676-2686. PubMed ID: 34536085
    [Abstract] [Full Text] [Related]

  • 14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 24; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Jun 24; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 16. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
    Hu J, Chen L.
    Prim Care Diabetes; 2021 Apr 24; 15(2):227-233. PubMed ID: 32888896
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):14. PubMed ID: 33413348
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.
    Cardiovasc Diabetol; 2017 Mar 01; 16(1):31. PubMed ID: 28249585
    [Abstract] [Full Text] [Related]

  • 20. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH, Udell JA, Filion KB.
    Trends Cardiovasc Med; 2017 Apr 01; 27(3):194-202. PubMed ID: 28291655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.